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Abstract In this work, the in vitro tests of biological activity
of benzimidazoles were conducted. This group of benzimid-
azole derivatives was evaluated as potential bioreductive
agents and their characteristic pro-apoptosis activity and cell
cycle interruption on the human lung adenocarcinoma A549
cells were discussed. Their toxicity on the healthy human
erythrocytes and their influence on the healthy human eryth-
rocytes acetylcholinesterase enzyme (AChE) were
established. Their apoptosis activity on A549 cells line was
determined by Annexin V-APC test, and it was visualized by
Hoechst test. In the next stage, their influence on the cell cycle
interruption was determined by using the ribonuclease re-
agent. The AChE inhibition test was defined by the Ellman
method, and the red blood cell lysis was defined by
erythrotoxicity test. The results proved the pro-apoptosis
properties of all tested compounds in normoxia and hypoxia.
The DNA content assay showed that the benzimidazoles
possess the ability to interrupt S phase of tumor cell cycle.
The best activity in this action was presented by compound
1, especially in hypoxia, and it proves that theN-oxide analogs
are predispositioned to the hypoxic target. In this study, the
benzimidazoles were found as potentially biocompatible and
their inhibition of acetylcholinesterase was lower than
tirapazamine and much lower than tacrine which constitutes
their desired effect of potential biological activity.
Keywords Anticancer activity . Benzimidazole derivatives .
Bioreductive agents . Cell cycle of benzimidazole . Toxicity of
benzimidazole
Introduction
The cancer ethiopathogenesis research plays a dominant
role in the global scientific trends. The focus is on the
bad epidemiological and demographic data concerning
the increasing mortality because of the malignant neo-
plasms. The most common globally recorded cancers are
the lung cancer in men and breast cancer in women [1, 2].
Still, the widely available methods of cancer treatment are
surgery, therapy with non-selective chemotherapeutic
agents, and radiotherapy or hormonal therapy [3]. While
the last listed method is strictly based on the environmental
change in tumor tissue, the cytostatic chemotherapy agents
or cytotoxic drugs generally do not possess the selective
antitumor activity. Most of them affect cell proliferation
and can damage normal tissue as well as, especially un-
changed, rapidly growing cells such as the bone marrow,
epithelial cells, gametocytes, or lymphatic cells. The sim-
ilar toxic effect on healthy tissue is exhibited by the most
popular methods of radiotherapy [4]. Systemic toxicity is
one of the major shortcomings of previously conducted
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anticancer therapies. Therefore, an effective anticancer
therapy should bear the properties of a relatively safe ther-
apy which will be revealed not only by radiotherapy and
chemotherapy dosages, but it must primarily take into ac-
count knowledge of the effect of the compounds on the cell
cycle. With assistance at searching the way for selectivity
therapy came the progress of the bioreductive drugs [5].
The bioreductive therapy uses hypoxia as the target for
main differences between normal and cancer cells [6]. An-
ticancer drugs because of their effect on cell division are
divided into non-specific, specific for the cycle and specif-
ic for the phase. The last class of potential anticancer
agents includes bioreductive agents with tirapazamine as
the most important representative of this class of com-
pounds [7–11]. The distinguishing characteristic feature
of these compounds from the group of cytotoxic sub-
stances is their selectivity for hypoxic cells which in turn
provides an opportunity to reduce the systemic toxic
effects.
The study conducted by our team provided the initial eval-
uation of the toxicity of new benzimidazole derivatives using
screening in vitro methods (erythrocyte hemolysis test and
AChE inhibition test) and determined the effect of our new
compounds on the interruption of the cycle of A549 cells
(human lung adenocarcinoma). In addition, an assessment of
the degree of differentiation of cells was tested. The division
into early or late apoptotic cells and necrotic was specified as a
function of the pro-apoptotic properties of tested benzimid-
azole derivatives.
Results and discussion
Benzimidazoles and their induction of the apoptosis
in A549 cells
Continuing studies on the cytotoxic activity of the new benz-
imidazole derivatives, the Annexin, and propidium iodide (PI)
assay were carried out (Fig. 1). This analysis allowed deter-
mining the pathway of tumor cell death which occurs under
the effect of the tested compounds. The participation of the
alive cells and cells in early apoptosis and late apoptosis or
necrosis in the population of A549 cells line was specified.
The fundamental problem concerned the evaluation and com-
parison of the degree of induced apoptosis and necrosis. With-
in the conducted experiments (test Annexin V + PI), the dom-
inance of early apoptotic cell population relating other cells
(late apoptotic and necrotic) was observed, both in the culture
performed in normoxia and hypoxia, in time up to 48 h
(Figs. 2 and 3). In a series of samples treated with the tested
compounds 1–4 under hypoxic conditions, the effect of sever-
ity of apoptosis cells was 60 % greater than in the control,
while in normoxia, it was higher only up to 50 %. Generally,
the results presented in Figs. 1, 2b, and 3b showed that hyp-
oxia induced early apoptosis to a greater extent than normoxia
for all tested substances. The strongest results proved com-
pound 1 (N-oxide) and next compound 2 (analog of com-
pound 1) (Figs. 2 and 3 parts B). Comparing the induction
of apoptosis under benzimidazole treatment with the induction
of apoptosis under the influence of tirapazamine, it can be
easily observed the beneficial pro-apoptotic effect of the tested
compounds especially under hypoxic conditions (Figs. 2 and
3 parts B). The highest difference between the effect of induc-
ing apoptosis in both series of the tested samples showed
compound 3 (58/74 % N/H) (Figs. 2 and 3 parts B). The
sequence of the other derivatives with the potency of induc-
tion of apoptosis in normoxia/ hypoxia is as follows: com-
pound 1 > 2 > 4 (Figs. 2 and 3 parts B). The analysis confirms
the selectivity of N-oxide (compounds 1, 3) under hypoxic
conditions and determines that the derivatives having the sub-
stituent nitrophenyl (compounds 1, 2) are suitable in their
apoptotic strength against the derivatives of substituent
chlorophenyl (compounds 3, 4).
The results of Annexin V and PI test were also confirmed
by the visualization of apoptotic cells in the analyzed samples
(Figs. 2 and 3 parts A). In normoxia, we observed a clear
effect of increasing the number of apoptotic cells compared
to the control in all tested assays (Figs. 2 and 3 parts A).
However, in hypoxia under the tested derivatives, the further
progress of apoptosis (there were a few cells non-apoptotic
visible in the field of vision) was seen and it led to necrosis
which has been observed on the basis of a far smaller number
of cells in the visual field (Figs. 2 and 3 parts A). It is worth
noticing that the increase of necrotic cell growth is a result of a
gradual cell death through apoptosis pathway and not through
a strong, immediate cytotoxic action of compounds. The
discussed results take into account the slight apoptosis and
poorer necrosis in the control cells in the tested samples in
both environments: normoxic and hypoxic.
Benzimidazole and their influence on the cell cycle
interruption
All tested compounds in normoxia and hypoxia had specific
effects on the cell cycle of A549 cells, causing particularly the
increase of the number of cells in the S phase replication,
while the growth of cells in the G0/1was inhibited. The largest
increase of the number of cells in S phase was induced by the
activity of compound 1. Additionally, compound 1 more
strongly inhibited the S phase in hypoxic conditions (the in-
crease 2.2-fold) than in normoxic environment (the increase
1.5-fold) (Fig. 4). Other compounds 2–4 showed the specific-
ity of inhibition of DNA synthesis in S phase in the conditions
of culture as well. It should be noted that the N-oxide deriva-
tives (compounds 1, 3) more strongly influence S phase under
hypoxic conditions than normoxic. In addition, the substituent
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nitrophenyl affects higher activity of the benzimidazole deriv-
atives than the chlorophenyl in both conditions. The conse-
quence of the inhibition of DNA synthesis in S phase was the
enhancement of the inhibition of the cell division in G2/M. All
tests were performed in comparison with the reference com-
pound tirapazamine, which the obtained results are consistent
with previously published results and confirm the selectivity
of them to the S phase of the cell cycle, particularly in hypoxia
(Fig. 5) [14].
Benzimidazoles and their lysis action
In this part of our experiments, the effect of four new com-
pounds (1–4) and two standards (camptothecin and
tirapazamine) on the human erythrocyte hemolysis was de-
fined. We observed that the highest concentration of com-
pounds 1, 2, and 3 slightly exceeded 10 % of hemolysis
compared to positive control (Triton X-100 at 0.2 %). Ten
percent of hemolysis is considered as the acceptable and
potentially safe level for the integrity of cell membranes.
Therefore, the compounds 1, 2, and 3 in the concentration
range between 2 to 100 μg/mL can be considered as bio-
compatible. Compound 4 proved its biocompatible in all
tested concentrations (% hemolysis does not exceed the
value of 10). Tirapazamine already at the lowest tested
concentration of 2 μg/mL caused hemolysis of greater than
10 %. The second reference substance camptothecin in the
tested concentrations showed no adverse effect on the
The A549 cells were exposed to IC50 of the tested compounds 1-4 for 48h 
Control Compound 2 Compound 1 Compound 3 Compound 4 Tirapazamine
N
H
Control Compound 2 Compound 4 Compound 1 Compound 3 Tirapazamine
PI 
Annexin-V-APC 
stronger apoptosis weaker apoptosis 
Fig. 1 Results of Annexin V-PI test for normoxia (N) and hypoxia (H). The A549 cells were exposed to IC50 of the tested compounds 1–4 for 48 h
Fig. 2 Visualization of apoptotic cells treated with the tested derivatives
and tirapazamine in normoxia. The percentage of different cell
populations identified by Hoechst (part A) and PI/Annexin V (part B)
assay. *p< 0.05 (mean +SD; n= 3), yellow arrows indicate normal cells,
and red arrows indicate apoptosis cells (c control, T tirapazamine,
compounds 1–4, apo apoptosis, nec necrosis)
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integrity of erythrocyte membranes. In this case, the des-
ignated % hemolysis of erythrocytes was not significantly
different from the sample incubated with the solvent
(DMSO) (Fig. 6).
The next stage of our in vitro biological activity studies
of tested compounds 1–4, tirapazamine, and camptothecin
toward inhibition of activity of human erythrocyte acetyl-
cholinesterase was performed. As presented in Fig. 7, all
compounds at the various concentrations contributed to
the statistically significant decrease of AChE activity.
Otherwise, tirapazamine in the whole range of used con-
centration (for example 75 μg/mL–0.4 mmol/min mL)
exerted the strongest inhibition of AChE. Comparing
IC50 values of compounds 1, 2, and 4 with IC50 value
of used standard camptothecin (Table 2), the lack of sta-
tistical difference between them was observed. Only IC50
of compound 3 was statistically significantly higher which
testifies to a much weaker impact of this compound on the
enzyme (889.5 ± 26.2/399.0 ± 55.9, p= 0.01). Comparing
IC50 values of all tested compounds with IC50 value of
the next used standard tirapazamine, the much lower in-
hibition was watched. In this aspect, our new compounds
as analogs of tirapazamine demonstrated potential lower
undesirable action. We used the third standard tacrine as a
typical AChE inhibitor. Regarding tacrine, our com-
pounds possess negligible inhibitory activity on this en-
zyme (Fig. 8).
The dependence of acetylcholinesterase inhibition obtained
during incubation of human erythrocytes of healthy volunteers
with various concentrations of examined compounds, as well
as IC50 values, is presented in Fig. 8 and Table 1. From these
results, we can make the proposal of correlation between in
vitro and in vivo action of the used new benzimidazoles. Both




The activity and the effect on the life processes of tumor cell
line A549 were related to new benzimidazole derivatives and
their analogs with N-oxide bond. The experiments were car-
ried out according to standard test procedures and based on
observations and modifications of the performed tests. The
used compounds were prepared according to the procedure
described earlier [12]. The concentration of the tested com-
pounds corresponded to the previously designated IC50 values
[13]. Tirapazamine has been used as a reference compound
due to its unique pro-apoptotic properties and high selectivity
to hypoxic conditions. Compounds were identified by num-
bers from 1 to 4, respectively (Table 2).
Cell culture
A549 cells— a human lung adenocarcinoma A549 cell
line— were purchased from the Health Protection Agency
Culture Collections (ECACC, Salisburgy, UK), cultured in
F12K medium (HyClone, Loughborough, UK) supple-
mented with 10 % heat-inactivated fetal bovine serum
(FBS) (Lonza, Basel, Switzerland), penicillin (10,000 U/
mL), and streptomycin (10,000 μg/mL) in 5 % CO2 at
37 °C. Hypoxic cells were obtained by culture of A549
cells in a hypoxic incubator in 1 % O2 and 5 % CO2 at
37 °C. The incubation at both conditions was conducted
for 24 h before treatment.
Morphological changes of the normoxic and hypoxic cells
as an effect of the activity of the tested compounds were eval-
uated with a phase-contrast microscope at ×100 magnification
(OptaTech, Warsaw, Poland).
Fig. 3 Visualization of apoptotic cells treated with the tested derivatives
and tirapazamine in hypoxia. The percentage of different cell populations
identified by Hoechst (part A) and PI/Annexin V (part B) assay. *p< 0.05
(mean + SD for three independent experiments; n = 3), yellow arrows
indicate normal cells, and red arrows indicate apoptosis cells (c control,
T tirapazamine, compounds 1–4, apo apoptosis, nec necrosis)
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The statistical data are expressed as mean±SD, by using
Student’s t test, n = 3 for each independent experiment.
*p<0.01 was considered significant.
Assessment of apoptosis and flow cytometry analysis
In T25 flasks, 5∗105 A549 cells were seeded for 24 h and
treated with benzimidazoles and tirapazamine for further 48 h.
The phosphate-buffered saline (PBS) was used for washing,
and the acutase was used for detaching. The detached cells
were diluted in buffer (100 μL/1∗105cells) containing APC-
conjugated Annexin V/ PI (4 μL/1∗105cells). Next, the incu-
bation was conducted for 20 min at dark area and room tem-
perature. After that time, the flow cytometry analysis was
carried out (FACS Canto II, Becton Dickinson, USA). The
apoptosis and necrosis populations were assessed by PI versus
Annexin V correlation. The cells stained with Annexin Vonly










Fig. 4 The percentage of cells in different phases of the cycle, after
application of the compound 1 and tirapazamine in normoxia (N) and
hypoxia (H). a Histogram of the flow cytometric DNA content for
compound 1 analysis. b Cell cycle specification for compound 1 (c con-
trol, T tirapazamine). *p< 0.05 (mean+ SD for three independent exper-
iments; n = 3)
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double-stained cells were recognized as late apoptosis or
necrosis.
Confocal visualization of apoptotic cells
In T25 flasks, 5∗105 A549 cells were seeded for 24 h and
treated with benzimidazoles and tirapazamine for further 48 h,
obtaining 80 % confluence of cell population. The PBS was
used for washing, and the acutase was used for culturing.
Next, the detached cells were washed and permeabilized by
70 % methanol at −21 °C. To the sample was added the opti-
mized amount of Hoechst 33342 (Thermo Scientific, Warsaw,
Poland) reagent at concentration 1 μg/mL. After 20 min of
incubation at room temperature, the positively stained
Fig. 5 The percentage of cells in various phases of the cycle, after
application of the compounds 1–4 and tirapazamine under normoxic
and hypoxic conditions. Cell cycle specification for all tested
compounds 1–4 (c control, T tirapazamine). p < 0.05 (mean + SD for
three independent experiments; n= 3)
Fig. 6 The percentage of red blood cell lysis obtained from the interaction compounds 1–4, camptothecin, and tirapazamine with human erythrocytes,
compared to the 100 % hemolysis; n= 5, *p= 0.05, **p= 0.06–0.001, ***p < 0.001 vs. control with DMSO
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population (dark-blue cells) was observed using confocal mi-
croscopy at ×100 magnification (Olympus bx61vs). The
percentage of different cell populations was identified by
Hoechst (part A) and PI/Annexin V (part B) assay. *p<0.05
Fig. 7 Influence of compounds 1–4, camptothecin, and tirapazamine on human erythrocyte acetylcholinesterase activity. n = 5, **p= 0.06–0.001,
***p< 0.001 vs. control
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(mean+SD; n=3), yellow arrows indicate normal cells, and
red arrows indicate apoptosis cells.
Measurement of DNA content by flow cytometry analysis
To tested compounds and control sample as well, 5∗ 105
A549 cells were exhibited and collected by using acutase.
The cells were washed with PBS and fixed in 70 % ethanol.
Next, the incubation with RNase (100 μg/mL, Sigma-Aldrich,
Munich, Germany) and PI (50 μg/mL, Sigma-Aldrich, Mu-
nich, Germany) was carried out for 30 min at dark space at
room temperature. The data from above 10,000 cells of each
sample were scanned by FACS Scan Canto II (Becton Dick-
inson, USA), and the amount of DNAwas analyzed.
Toxicity assay
Reagents
We used 0.9 % physiological sodium chloride solution
(0.15 mol/L) and 0.1 mol/L phosphate buffer (pH=7.0 and
pH = 8.0) prepared from reagents obtained from Polish
Chemical Reagents (Gliwice, Poland). The 5,5 ′-
dithiobisnitrobenzoic acid (DTNB) and acetylthiocholine io-
dide (enzyme substrate) were obtained from Sigma-
Aldrich (Munich, Germany). Exactly before the experiments,
DTNB (0.1 mol/L) with phosphate buffer pH = 7.0 and
acetylthiocholine iodide (21.67 mg/mL) with distilled water
were diluted. Triton X-100C was obtained from Polish Chem-
ical Reagents (Poland). Tacrine (Sigma-Aldrich, Munich,
Germany) was used as a standard non-competitive inhibitor
of acetylcholinesterase.
Materials
Blood samples were taken from healthy donors using a vacu-
um tube with potassium versenate. Collection was taken at the
Regional Blood Donation and Hemotherapy Centre, Lodz.
Erythrocytes were separated from the plasma and leucocytes
by centrifugation (3000×g, 10 min) at 4 °C and washed three
times with 0.9 % saline. The hemolyzed human erythrocytes
for acetylcholinesterase (AChE) activity determination were
used. They were stored at −30 °C until the measurements were
taken. Immediately prior to eachmeasurement, the hemolyzed
erythrocytes were restored at 37 °C for 30 min. Once thawed,
hemolyzed erythrocytes were not frozen again and were not
used for retesting.
Methods
Activity of human erythrocyte acetylcholinesterase (AChE)
was defined spectrophotometrically according to the Ellman

























N 460,0 1,5 169,2 2,5 24,4 2,6 36,6 1,8 162,2 0,6
H 96,8 1,9 97,4 1,4 56,0 2,5 56,8 1,5 29,0 1,5
a Data are expressed as the mean± SD, n= 3
Table 1 The IC50 values for
activities toward human
erythrocyte acetylcholinesterase




dards of AChE inhibition)
Compound IC50 (μmol/L) Comparison with IC50 of standards
Camptothecin Tirapazamine Tacrine
399.0 ± 55.9 143.8 ± 53.8 0.239± 0.09
1 377.4 ± 59.4 NS; (p = 0.608) p< 0.001 p< 0.001
2 372.9 + 59.4 NS; (p = 0.719) p< 0.001 p< 0.001
3 889.5 ± 26.2 p= 0.01 p< 0.001 p< 0.001
4 306.8 ± 48.2 NS; ( p= 0.06) p< 0.001 p< 0.001
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[17] method with some modifications [18]. The freshly
thawed erythrocytes in phosphate buffer (pH 8) were diluted
(1:400). The 0.960 mL of this solution, 0.010 mL of DTNB
solution (1 μmol/mL), and 0.020 mL of examined compound
at concentration ranging from 2 to 150 μg/mL or appropriate
volume of diluent were added to the cuvette and incubated for
5 min at 37 °C. To start the enzymatic reaction, 0.010 mL of
acetylthiocholine iodide (0.75 μmol/L) was added. The con-
tinuous measurements of absorbance were performed at a
wavelength of λ=436 nm by means of a spectrophotometer
(Cecil CE2021, London, England) at 37 °C for 6 min. The
results were saved and analyzed with DATA STREAM
CE3000 5.0 software. The activity of human erythrocyte
AChE was calculated automatically, according to equation
E=Δ Abs /F and expressed as [μg/min mL], where E—ac-
tivity of AChE,Δ A—velocity of reaction [OD/min], and F—
factor (F=dilution/absorption coefficient for the [TNB-]). The
absorption coefficient for the [TNB−] ion in assay conditions
was 10.6 mM−1 cm−1. AChE inhibition, expressed in %, was
calculated using the equation ((A0−AIC)∗100 %) /A0, where
A0 means AChE activity in the control sample, expressed as
the rate of the enzymatic velocity [A/min], and AIC—AChE
activity in the sample of examined compounds or reference
standard, expressed, as above, as the rate of the enzymatic
reaction [OD/min]. The IC50 value, defined as the drug con-
centration that inhibits 50 % AChE activity, was determined
from a fitted sigmoidal concentration–response curve.
Statistics analysis
All values of measured parameters were expressed as means
±SD. The Q-Dixon test to reject the results unreliable was
used. Statistical tests were performed using a commercial soft-
ware package (Statistica 10.0, StatSoft). The Shapiro–Wilk
test was applied to determine whether the continuous variables
were normally distributed. The t test was used to compare
variables which showed normal distributions, while the
Mann-Whitney test was used for variables showing non-
normal distributions. A p value of less than 0.05 was consid-
ered as statistically significant.
Assay of red blood cell lysis
Assay of red blood cell lysis according to the early described
method was performed [19]. Briefly, red blood cells at con-
centration of 2 % were incubated at 37 °C with compounds at
concentration ranging from 2 to 150 μg/mL. After 1 h of
incubation, the samples were centrifuged at 3000 rpm for
10 min and the absorbance of the supernatant was measured
at 550 nm. Hemolysis of RBCs was expressed as percentage
of released hemoglobin. A solution of RBCs incubated with
Triton X-100 (0.2 % v/v) was used for determination of 100 %
of hemoglobin release. A control with diluent (water or
DMSO) was used to determine spontaneous hemolysis of
RBCs and to compare it with hemolysis caused by investigat-
ed substances.
Conclusions
Performing further analysis of the biological activity of the
new benzimidazole derivatives with potential antitumor activ-
ity, the effect of these compounds on the disintegration of the
cells in the cascade of pathological events of pro-apoptosis
through apoptosis to necrosis as a phenomenon leading to
the gradual but effective cancer cell death was determined.
The performed tests showed pro-apoptotic properties of the
tested compounds related to their ability to induce significant
apoptosis in both normoxia and hypoxia conditions and the
immediate elimination of the undesirable necrosis. These re-
sults confirm the preferred biological parameters of new benz-
imidazole derivatives especially in the context of the
searching for new cytotoxic compounds from the group of
selective anticancer agents. Our research conducted in
normoxia and hypoxia proved the stability of these properties
and clearly indicated the structure of the N-oxide as the factor
ensuring the selectivity in hypoxia. With regard to the refer-
ence compound, the level of activity of all tested compounds
is high, which demonstrates the accuracy of the selection of
the studied structure with the characteristic substituents of the
benzimidazole ring.
All tested benzimidazole derivatives also showed the DNA
damaging potential. Because of their action on the cell cycle,
they stopped the replication in S phase. By this property, on
the one hand, they allow efficient transition of cells to a con-
trolled way of death. On the other hand, they more strongly
inhibit the topoisomerase I activity [15, 16] at the same time,
and consequently, they promote damage to the genetic mate-
rial of tumor cells. In comparison to the reference compound,
N-oxide 2-(2-nitrophenyl)-1H-benzimidazole (compound 1)
possesses the greater degree of action on the cell cycle in
hypoxia. Probably, it is due to the presence of N-oxide func-
tion of its structure, because such studied analogs showed
higher activity with respect to derivatives without these
groups. This conclusion is derived from the fact (what we
observed during our experiments) that the increase of the ac-
tivity of derivatives of benzimidazole is correlated with the
presence of the N-oxide bond. The analogous situation con-
cerns derivatives with nitro group (the nitrophenyl substitu-
ent). They possess the higher activity relative to the deriva-
tives with chloro group (the chlorophenyl substituent). In
comparison to all other tested derivatives of benzimidazole
and also relative to the reference compound, the most active
in the context of the impact on the life processes of tumor cells
is N-oxide 2-(2-nitrophenyl)-1H-benzimidazole (compound
1). First of all, it was characterized by the greatest specificity
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to hypoxic conditions. Satisfactory results were also achieved
for its analog, not having the structure of N-oxide (compound
2). The study of benzimidazole biological activity should be
continued especially as an aspect of broadening cell line types.
This would allow evaluating their features against different
types of tumors.
In this study, biocompatibility of the newly synthesized
compounds and standards by means of the assay of the eryth-
rocyte lysis was assessed as well. According to previous stud-
ies, less than 10 % of hemolysis is not considered cytotoxic
[19]. Comparing the effects of the tested compounds and
tirapazamine (standard substance) on the integrity of the eryth-
rocyte membrane, it can be concluded that the newly synthe-
sized compounds have a less adverse effect on the membrane
of the erythrocytes. Tirapazamine already at the lowest test
concentration of 2 μg/mL caused greater than 10 % hemoly-
sis. The second reference substance camptothecin in the tested
concentrations showed no adverse effect on the integrity of
erythrocyte membranes. In this case, the designated % hemo-
lysis of erythrocytes was not significantly different from the
sample incubated with the solvent (DMSO). The
erythrotoxicity test results indicate that the tested newly syn-
thesized compounds can be considered potentially biocompat-
ible, which can make a positive contribution for further testing
of these compounds in animals.
In the next stage of the study, the effect of new benzimid-
azole derivatives on the activity of human erythrocyte AChE
was conducted. The tested compounds were designed as in-
hibitors of topoisomerase I [13]. From literature, it is known
that camptothecin and other inhibitors of topoisomerase I also
tend to result in the inhibition of AChE [20, 21]. Using them
can cause the cholinergic syndrome, usually mild, although
this is one of the main reasons for cancelling such drugs from
the treatment in the anticancer therapy. [17]. In our studies, we
used the adapted in vitro testing of the new compounds, i.e.,
the method of Ellman [17]. It is the reference method used in
the laboratory diagnosis of acute poisonings among other or-
ganophosphorus pesticides that are potent inhibitors of AChE.
This method is also used in vitro and in vivo assays to assess
the efficacy of oxime for the reactivation of AChE.
The AChE is an essential enzyme primarily expressed in
the central and peripheral nervous systems. However, differ-
ent isoforms of AChE are also constitutive of various cell
types, e.g., human fibroblasts, osteoblasts, kidney cells, eryth-
rocytes, vascular endothelial cells, and leukocytes, as well as
lung, and spleen cells. It is well established that the biological
role of AChE is not limited to its classical role in hydrolyzing
acetylcholine. In many kinds of tissue, AChE plays non-
classical functions such as the influence on apoptotic sensitiv-
ity, cellular proliferation, and differentiation, suggesting a pos-
sible role of cholinesterases in tumorigenesis and stress re-
sponses related to inflammation. Furthermore, abnormal ex-
pression and structural alteration of AChE and multiple
activities have been found in different types of tumors, such
as brain, lung, ovarian, breast, hepatocellular, renal, and colon
cancers, which indicate the involvement of AChE in regulat-
ing the tumor development. However, the role of AChE in
tumor progression remains unclear [19, 20, 21].
Our research has shown that all tested compounds with
different strengths inhibit the enzymatic activity of human
erythrocyte AChE. The experiments showed that the weakest
substance is compound 3 (it has got statistically significantly
higher IC50 value compared with camptothecin). IC50 values
for compounds 1, 2, and 4 did not differ significantly from the
value of camptothecin IC50 (standard), which may indicate
comparable tendency to induce a side effect. In literature, there
is no research on the effects of tirapazamine on the activity of
AChE. What is interesting, tirapazamine proved its strongest
power according to all tested compounds—its IC50 was statis-
tically lower than of all other tested compounds. Currently, the
third phase of clinical trials of this compound is ongoing [22].
It is known that in addition to neutropenia, one of the most
frequently reported symptoms of toxicity occurring in the ap-
proach of the anticancer therapy is nausea, vomiting, and di-
arrhea of unknown etiology. These are non-specific symp-
toms, but they can appear as a result of excessive inhibition
of AChE by tirapazamine as well [17].
However, it is worth emphasizing that the inhibition of
AChE observed in our study is not particularly strong. In order
to compare, the IC50 value was determined for tacrine, the
strong typical inhibitor of AChE activity. The IC50 value of
tacrine was statistically significantly lower than for all the
tested compounds.
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